American Society of Hirudotherapy

Vampire Venom: Vasodilatory Mechanisms of Vampire Bat (Desmodus rotundus) Blood Feeding

Basic science / comparative published in Toxins (2019)

Last Updated: June 18, 2026Reviewed by: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Preclinical (animal)Salivary PharmacologyDrug DevelopmentKakumanu R et al. · Toxins, 2019

Abstract

Animals that specialise in blood feeding have particular challenges in obtaining their meal, whereby they impair blood hemostasis by promoting anticoagulation and vasodilation in order to facilitate feeding. These convergent selection pressures have been studied in a number of lineages, ranging from fleas to leeches. However, the vampire bat (Desmondus rotundus) is unstudied in regards to potential vasodilatory mechanisms of their feeding secretions (which are a type of venom). This is despite the intense investigations of their anticoagulant properties which have demonstrated that D. rotundus venom contains strong anticoagulant and proteolytic activities which delay the formation of blood clots and interfere with the blood coagulation cascade. In this study, we identified and tested a compound from D. rotundus venom that is similar in size and amino acid sequence to human calcitonin gene-related peptide (CGRP) which has potent vasodilatory properties. We found that the vampire bat-derived form of CGRP (i.e., vCGRP) selectively caused endothelium-independent relaxation of pre-contracted rat small mesenteric arteries. The vasorelaxant efficacy and potency of vCGRP were similar to that of CGRP, in activating CGRP receptors and Kv channels to relax arteriole smooth muscle, which would facilitate blood meal feeding by promoting continual blood flow. Our results provide, for the first time, a detailed investigation into the identification and function of a vasodilatory peptide found in D. rotundus venom, which provides a basis in understanding the convergent pathways and selectivity of hematophagous venoms. These unique peptides also show excellent drug design and development potential, thus highlighting the social and economic value of venomous animals.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article
Indexed MeSH termsAnimalsChiropteraFeeding BehaviorMaleMesenteric ArteriesRats, Sprague-DawleyVasodilationVenoms

Summary

Researchers identified a CGRP-like peptide (vCGRP) in vampire bat (Desmodus rotundus) venom that causes endothelium-independent relaxation of pre-contracted rat small mesenteric arteries, acting through CGRP receptors and Kv channels similarly to CGRP itself, aiding blood-meal feeding.

Context

This study identified and characterized a vasodilatory peptide from vampire bat (Desmodus rotundus) venom that resembles human calcitonin gene-related peptide (CGRP). The bat-derived vCGRP caused endothelium-independent relaxation of pre-contracted rat mesenteric arteries via CGRP receptors and Kv channels, with efficacy and potency similar to human CGRP. The authors frame this within convergent hematophagous venom evolution, explicitly referencing leeches among blood-feeding lineages subject to similar selective pressures for anticoagulation and vasodilation. No leech-derived molecules were tested, and the study is solely a vampire bat venom investigation in rats and isolated arteries, with no comparison with leech secretome constituents.

Citation

Reference (Vancouver style)

Kakumanu R, Hodgson WC, Ravi R, Alagon A, Harris RJ, Brust A, et al. Vampire Venom: Vasodilatory Mechanisms of Vampire Bat (Desmodus rotundus) Blood Feeding. Toxins (Basel). 2019;11(1):26. doi:10.3390/toxins11010026. PMID: 30626071

Bibliographic details (authors, volume, pages, DOI) are taken from the PubMed record.

Added to ASH library: May 27, 2026 · Site last updated: June 18, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.